Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
07/06/2026 11:08
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports June 7 (Reuters) - US biotech Incyte Pharma INCY.O is nearing a deal for up to $2 billion to buy blood disorder drug developer Star Therapeutics, the Financial Times reported on Sunday, citing people familiar with the matter.
The biotechnology company is set to pay $1.25 billion upfront in cash to Star’s venture capital backers and a further $750 million based on certain performance milestones being met, the report said.
Reuters could not immediately verify the report.
(Reporting by Preetika Parashuraman in Bengaluru
Editing by Tomasz Janowski)
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler